Pricing Log in Create free account

Monte Rosa Therapeutics, Inc. (GLUE) vs Kura Oncology, Inc. (KURA)

Monte Rosa Therapeutics, Inc. and Kura Oncology, Inc. are both Biotechnology companies. Monte Rosa Therapeutics, Inc. and Kura Oncology, Inc. are of similar size ($863.4M and $862.9M). Kura Oncology, Inc. has the higher net margin (−384.3% vs −560.9%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Monte Rosa Therapeutics, Inc. leads on 10 and Kura Oncology, Inc. on 5.

Valuation

Metric GLUE KURA Biotechnology median
P/E n/m n/m 8.50
P/S 34.41 10.45 9.71
P/B 2.03 16.66 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 12.79 3.85 9.21
Earnings yield (18.07%) (37.11%) (33.15%)
Free cash flow yield (3.25%) (14.55%) (25.50%)

Profitability

Metric GLUE KURA Biotechnology median
Gross margin 100.00% 99.35% 65.16%
Operating margin (633.04%) (411.90%) 0.00%
Net margin (560.85%) (384.30%) 0.00%
Free cash flow margin (111.66%) (152.06%) 0.00%
Return on equity (42.66%) (167.71%) (56.36%)
Return on assets (30.67%) (46.73%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric GLUE KURA Biotechnology median
Revenue growth (TTM) (83.86%) — 6.02%
EPS growth (last fiscal year) 53.06% (57.43%) 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GLUE KURA Biotechnology median
Debt to equity 0.00 0.20 0.00
Current ratio 10.58 4.73 4.72
Net debt to EBITDA 8.22 2.11 0.96

Dividend

Metric GLUE KURA Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric GLUE KURA Biotechnology median
Market cap 863.37m 862.92m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack